Business Context and Reporting Period
This Form 8-K was filed by Trovagene, Inc. on September 6, 2013. The report discloses a material event occurring on the same date. Note: The request metadata references "Cardiff Oncology, Inc.," but the filing text explicitly identifies the registrant as "Trovagene, Inc."
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a corporate event rather than financial performance data.
Material Changes
On September 6, 2013, Trovagene, Inc. entered into a clinical collaboration agreement with the University of Southern California. The agreement involves studying genomic characterizations of metastatic colorectal cancers using the Company's proprietary cell-free DNA assays.
Guidance, Outlook, and Risks
The filing does not contain specific financial guidance, management commentary on future outlook, or a discussion of risks and contingencies beyond the disclosure of the new collaboration. The press release detailing the agreement is furnished as Exhibit 99.1 but is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.
Investor Verification Checklist
- Verify the exact terms and duration of the clinical collaboration agreement with the University of Southern California.
- Confirm the specific scope of the genomic characterization study for metastatic colorectal cancers.
- Review the full text of the press release provided as Exhibit 99.1 for additional details not summarized in the 8-K.
- Clarify the discrepancy between the requested company name (Cardiff Oncology, Inc.) and the filing registrant (Trovagene, Inc.).